Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006108 · ClinicalTrials.gov registry record · NA
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02006108: Completed NA study, sponsored by Stanford University.
NCT02006108 is a NA study that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02006108, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a renal allograft on Ferumoxytol-MRI demonstrates significant differences between rejected and non-rejected transplants.
Interventions
- DRUG Feraheme
- OTHER MRI-GE Healthcare 3 Tesla magnet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-11-27 |
| Est. Completion | 2017-04-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006108
The ClinicalTrials.gov registry entry for NCT02006108 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Feraheme is the first listed.
NCT02006108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02006108 about?
NCT02006108 is a clinical study titled "Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance". The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a renal allograft on Ferumoxy...
What is the current status of trial NCT02006108?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2012-11-27. Estimated completion is 2017-04-11.
What interventions are being tested in trial NCT02006108?
The interventions under investigation include: Feraheme (DRUG), MRI-GE Healthcare 3 Tesla magnet (OTHER).
Who is sponsoring clinical trial NCT02006108?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.